Core Viewpoint - Maiwei Biotech (688062.SH) is expected to continue reporting a net loss attributable to shareholders in 2025, with projected losses ranging from -900 million to -994.5 million yuan [1] Financial Performance - The company's operating revenue is anticipated to increase significantly compared to the previous year, primarily due to substantial income recognized from licensing agreements with Qilu Pharmaceutical Co., Ltd. and DISCMEDICINE, INC., along with a notable rise in drug sales revenue [1] - The expected net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between -905 million and -999.5 million yuan [1] Cost and Investment Factors - As commercialization expands, both operating costs and sales expenses are expected to rise correspondingly [1] - The company is maintaining a high level of research and development investment, with multiple innovative drugs currently in critical trial phases [1]

Core Viewpoint - The company, Maiwei Biotech, is expected to continue incurring losses in 2025, with projected net losses ranging from 900 million to 995 million yuan, compared to a loss of 1.044 billion yuan in the previous year [1] Financial Performance - The projected net profit attributable to the parent company for 2025 is expected to be a loss of 900 million to 995 million yuan, while the net profit after deducting non-recurring gains and losses is anticipated to be a loss of 905 million to 999 million yuan [1] - In the previous year, the company reported a net loss of 1.044 billion yuan attributable to the parent company, with a net loss of 1.07 billion yuan after excluding non-recurring items [1] Revenue Growth - The company has seen a significant increase in operating revenue compared to the previous year, primarily due to substantial income recognized from licensing agreements with Qilu Pharmaceutical Co., Ltd. and DISC MEDICINE, INC., as well as a notable increase in drug sales revenue [1]

Financial Performance - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -900 million and -994.5 million yuan, indicating continued losses compared to the previous year [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -905 million and -999.5 million yuan [2]. - The total profit for the previous year was -1,047.47 million yuan, with a net profit attributable to shareholders of -1,043.92 million yuan [3]. - The company will continue to report negative net profit attributable to shareholders for the 2025 fiscal year [6]. Revenue and Costs - The company reported a significant increase in operating income due to large revenue recognition from licensing agreements and increased drug sales compared to the previous year [4]. - Operating costs and sales expenses have increased in line with the expansion of commercialization efforts [4]. Research and Development - The company maintains a high level of R&D investment as multiple innovative drugs are in critical trial stages [4]. Forecast and Uncertainties - There are no significant uncertainties affecting the accuracy of this earnings forecast [7]. - The forecast data is preliminary and subject to change pending the audited financial report for 2025 [8].

Group 1 - The chemical sector continues to rise, with the Chemical ETF (516020) showing a 0.31% increase as of January 23 [1] - Key stocks in the sector include Dongfang Shenghong, Weixing Chemical, and Hongda Co., which have all seen gains exceeding 4% [1] - The Chemical ETF has attracted significant investment, with a net subscription amount close to 1.2 billion yuan over the last five trading days [2] Group 2 - Recent petrochemical projects have been included in the key engineering project list for 2026, providing strong support for the industry [3] - The National Development and Reform Commission has allocated special bonds to support energy-saving and environmental protection initiatives [3] - The chemical industry is entering a strategic window, with high-cost overseas marginal capacity exiting and a restructuring of the global chemical order [3] Group 3 - Analysts are optimistic about the chemical sector's recovery, driven by changes in corporate strategies and market dynamics [3] - Key areas of focus for investment include MDI, petrochemicals, phosphate chemicals, PVC, and polyester bottle chips [3] - The Chemical ETF (516020) is recommended as an efficient way to gain exposure to the sector, tracking the CSI sub-industry index [3]

Core Viewpoint - Maiwei Biotech announced the decision to utilize up to 800 million yuan of temporarily idle raised funds for cash management over a 12-month period, with the option for rolling use [1] Group 1: Financial Management - The net amount of raised funds as of June 30, 2025, is approximately 3.303 billion yuan [1] - 48.45% of the raised funds have been invested in antibody industrialization and other projects [1] - The highest single-day investment in cash management over the last 12 months was about 357 million yuan, with a principal amount of 38.77 million yuan yet to be recovered [1]

国泰海通证券股份有限公司 关于迈威（上海）生物科技股份有限公司 继续使用部分暂时闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为迈 威（上海）生物科技股份有限公司（以下简称"迈威生物"、"公司"或"发行人"） 首次公开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理 办法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》等 有关法律法规和规范性文件的要求，就迈威生物继续使用暂时闲置募集资金进行 现金管理的事项进行了审慎核查，并发表如下核查意见： 一、投资情况概述 （一）投资目的 1、投资品种 为提高募集资金使用效率，在不影响募投项目开展、募集资金使用计划和保 证募集资金安全的前提下，公司及全资子公司拟继续利用部分暂时闲置募集资金 进行现金管理，提高募集资金使用效益、增加股东回报。 （二）投资金额 在保证不影响公司募集资金投资计划正常进行的前提下，公司及全资子公司 拟继续使用最高不超过人民币 8 亿元的暂时闲置募集资金进行现金管理，使用期 限自董事会审议通过之日起 12 个月内有效，在前述额度及使用期限范围内，资 金可以循环滚动使 ...

证券代码：688062 证券简称：迈威生物 公告编号：2026-001 迈威（上海）生物科技股份有限公司 关于预计 2026 年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否需要提交股东会审议：否 日常关联交易对上市公司的影响：公司预计的 2026 年日常关联交易，是 基于公司和关联方之间的正常生产经营需要进行。关联交易遵循公平合理的定价 原则，不存在损害公司及股东特别是中小股东利益的情形，公司对关联方也不会 形成依赖，也不会影响公司的独立性。公司与上述关联人保持较为稳定的合作关 系，在公司业务存在切实需求的情况下，与上述关联人之间的关联交易将持续存 在。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 1、公司董事会审计委员会审议程序 公司于2026年1月16日召开第二届董事会审计委员会第二十次会议，通过了 《关于预计2026年度日常关联交易的议案》，并同意将该议案提交至公司董事会 审议。 2、公司董事会审议程序 公司于2026年1月21日召开第二届董事会第二十七次 ...

投资种类：安全性高、流动性好、有保本约定的投资产品（包括但不限 于结构性存款、通知存款、定期存款、大额存单、协定存款等） 证券代码：688062 证券简称：迈威生物 公告编号：2026-002 迈威（上海）生物科技股份有限公司 关于继续使用部分暂时闲置募集资金进行现金管理 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资金额：不超过人民币 8 亿元（含本数） 已履行的审议程序：迈威（上海）生物科技股份有限公司（以下简称"迈 威生物"或"公司"）于 2026 年 1 月 21 日召开第二届董事会第二十七次会议， 审议通过了《关于继续使用部分暂时闲置募集资金进行现金管理的议案》，该事 项在公司董事会审批权限范围内，无需提交股东会审议。保荐机构国泰海通证券 股份有限公司对上述事项出具了明确同意的核查意见。 特别风险提示：尽管公司选择低风险投资品种的现金管理产品，但金融 市场主要受货币政策等宏观经济的影响，公司将根据经济形势以及金融市场的变 化适时适量的介入，但不排除该项投资受到市场波动的影响。 一、投资情 ...

南财智讯1月21日电，迈威生物公告，公司于2026年1月21日召开第二届董事会第二十七次会议，审议通 过了《关于继续使用部分暂时闲置募集资金进行现金管理的议案》。公司及全资子公司拟使用最高不超 过8.00亿元的暂时闲置募集资金进行现金管理，在额度及使用期限范围内资金可滚动使用，有效期自董 事会审议通过之日起12个月内有效。投资方向为购买安全性高、流动性好、有保本约定的投资产品，包 括但不限于结构性存款、通知存款、定期存款、大额存单、协定存款等。公司强调，该事项不会影响募 集资金投资项目进度和公司正常生产经营。 ...

东方创新医疗股票A（018045）成立日期2023年5月8日，最新规模1070.2万。今年以来收益8.85%，同 类排名1479/5542；近一年收益34.05%，同类排名2266/4235；成立以来收益8.43%。 东方创新医疗股票A（018045）基金经理为蔡尚军。 截至发稿，蔡尚军累计任职时间1年335天，现任基金资产总规模5488.34万元，任职期间最佳基金回报 10.94%， 任职期间最差基金回报1.41%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 1月20日，迈威生物跌5%，截至发稿，报39.88元/股，成交2.72亿元，换手率3.28%，总市值159.36亿 元。 资料显示，迈威(上海)生物科技股份有限公司位于中国(上海)自由贸易试验区蔡伦路230号2幢105室香港 铜锣湾希慎道33号利园1期19楼1928室，成立日期2017年5月12日，上市日期2022年1月18日，公司主营 业务涉及治疗用生物制品的研发、生产与销售。主营业务收入构成为：销售商品9 ...